Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Indapamide
Drug ID BADD_D01149
Description The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension.[A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally.[A204155] Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets.[A204155] Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency.[A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes.[A204134] Interestingly, unlike thiazide diuretics, several sources suggest that indapamide is not associated with glucose or lipid disturbances.[A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility.[A204158]
Indications and Usage Indapamide is a diuretic indicated for use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension.[L13982] It may also be used to treat fluid and salt retention associated with congestive heart failure.[L13982]
Marketing Status approved
ATC Code C03BA11
DrugBank ID DB00808
KEGG ID D00345
MeSH ID D007190
PubChem ID 3702
TTD Drug ID D0H8FH
NDC Product Code 63190-0200; 63629-1953; 71335-1541; 57451-1171; 0228-2597; 16571-875; 68788-7247; 62559-511; 63809-1053; 62559-510; 51407-024; 63629-1954; 0378-0069; 51407-025; 53069-0090; 0228-2571; 0378-0080; 16571-876
UNII F089I0511L
Synonyms Indapamide | Metindamide | S-1520 | S 1520 | S1520 | SE-1520 | SE 1520 | SE1520
Chemical Information
Molecular Formula C16H16ClN3O3S
CAS Registry Number 26807-65-8
SMILES CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis noninfective20.03.02.001--
Choroidal effusion06.09.01.0080.000754%-
Ventricular tachyarrhythmia02.03.04.0120.000377%-
Skin mass23.07.04.014---
Brain injury17.11.01.003; 19.07.03.0070.000377%-
Acute kidney injury20.01.03.0160.006218%
Osmotic demyelination syndrome17.16.02.0040.000754%-
Toxicity to various agents12.03.01.046---
Candida infection11.03.03.021--
Stasis dermatitis23.03.04.041; 24.10.04.0040.000377%-
Hypertensive emergency24.08.01.0040.000377%-
Necrotising myositis15.05.05.0160.000754%-
Immune-mediated myositis10.02.01.088; 15.05.01.0120.000754%-
Osteochondrodysplasia03.11.03.002; 15.11.03.002---
Vulvovaginal inflammation21.14.02.014---
The 10th Page    First    Pre   10    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene